GLP-1 and Its Analogs: Does Sex Matter?
Endocrinology · 06.01.2025 · 166 (2)
DOI: 10.1210/endocr/bqae165 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, online erschienen am 23.12.2024. Verfasst von Stina Börchers und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology/Metabolic Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 413…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Sex Characteristics. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
While obesity and diabetes are prevalent in both men and women, some aspects of these diseases differ by sex. A new blockbuster class of therapeutics, glucagon-like peptide 1 (GLP-1) analogs (eg, semaglutide), shows promise at curbing both diseases. This review addresses the topic of sex differences in the endogenous and therapeutic actions of GLP-1 and its analogs. Work on sex differences in human studies and animal research is reviewed. Preclinical data on the mechanisms of potential sex differences in the endogenous GLP-1 system as well as the therapeutic effect of GLP-1 analogs, focusing on the effects of the drugs on the brain and behavior relating to appetite and metabolism, are highlighted. Moreover, recent clinical evidence of sex differences in the therapeutic effects of GLP-1 analogs in obesity, diabetes, and cardiovascular disease are discussed. Lastly, we review evidence for the role of GLP-1 analogs in mood and reproductive function, with particular attention to sex differences. Overall, while we did not find evidence for many qualitative sex differences in the therapeutic effect of clinically approved GLP-1 analogs, a growing body of literature highlights quantitative sex differences in the response to GLP-1 and its analogs as well as an interaction of these therapeutics with estrogens. What also clearly emerges is the paucity of data in female animal models or women in very basic aspects of the science of GLP-1—gaps that should be urgently mended, given the growing popularity of these medications, especially in women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology/Metabolic Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 41390 Gothenburg, Sweden.
- Nutritional Sciences Department, The Pennsylvania State University, University Park, PA 16803, USA.
- Huck Institutes of Life Science, The Pennsylvania State University, University Park, PA 16803, USA.
ORCID-Profile: Karolina P Skibicka
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Börchers, S., & Skibicka, K. P. (2025). GLP-1 and Its Analogs: Does Sex Matter?. Endocrinology, 166(2). https://doi.org/10.1210/endocr/bqae165
Vancouver
Börchers S, Skibicka KP. GLP-1 and Its Analogs: Does Sex Matter?. Endocrinology. 2025;166(2). doi:10.1210/endocr/bqae165
BibTeX
@article{Brchers2025,
author = {Börchers, Stina and Skibicka, Karolina P},
title = {GLP-1 and Its Analogs: Does Sex Matter?},
journal = {Endocrinology},
year = {2025},
volume = {166},
number = {2},
doi = {10.1210/endocr/bqae165}
}
EUVIMED